Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00610493 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab and Temsirolimus in Patients With Advanced Malignancy
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 193
- Enrollment target
NCT00610493: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00610493 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 193 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (222% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00610493, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 193 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of Avastin (bevacizumab) and Torisel (temsirolimus) that can be given, in combination, to patients with advanced cancer that has spread or is unable to be surgically removed. The safety of this drug combination will also be studied.
Primary Outcome
Maximum tolerated dose defined as the dose level below the dose at which two of six patients experience drug-related dose limiting toxicity in the first cycle.
Interventions
- DRUG Bevacizumab
- PROCEDURE Biopsy
- DRUG Temsirolimus
- PROCEDURE Additional Blood Drawn
- PROCEDURE DCE-MRI Scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2008-01-25 |
| Est. Completion | 2017-11-28 |
| Phase | Phase 1 |
What the finished NCT00610493 record still lists
NCT00610493 is an interventional study that assigns participants to a tested intervention. The registered 193 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (222% higher).
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00610493 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00610493 about?
NCT00610493 is a clinical study titled "Bevacizumab and Temsirolimus in Patients With Advanced Malignancy". The goal of this clinical research study is to find the highest tolerable dose of Avastin (bevacizumab) and Torisel (temsirolimus) that can be given, in combination, to patients with advanced cancer that has spread or is unable to be surgically removed. The safety of this drug combination will also ...
What is the current status of trial NCT00610493?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 193 participants. The study started on 2008-01-25. Estimated completion is 2017-11-28.
What interventions are being tested in trial NCT00610493?
The interventions under investigation include: Bevacizumab (DRUG), Biopsy (PROCEDURE), Temsirolimus (DRUG), Additional Blood Drawn (PROCEDURE), DCE-MRI Scan (PROCEDURE).
Who is sponsoring clinical trial NCT00610493?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00610493's enrollment target sits among peer trials
193 282nd of 2000 higher than 1,719 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06226220 · 193 participants · NA
Percutaneous Nerve Evaluation Trial Time
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI